Primer on Tumor Immunology and Cancer Immunotherapy™

November 9, 2017 • 8 a.m.-5 p.m.


Program Purpose

Our understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer.

Intended Audience

The intended audience for this annual, one-day educational program includes students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy.

Educational Objectives

Upon completion of this meeting, participants will be able to:

  • Describe the key principles of tumor immunology and immunotherapy
  • Summarize the basic principles of passive immunotherapy, in which antibodies or T lymphocytes generated outside of the patient are administered with therapeutic intent
  • Discuss the techniques involved in active immunotherapy, including tumor antigen vaccination as well as immune checkpoint blockade
  • Outline immune monitoring techniques, both in peripheral blood and sera, as well as in patient samples collected in pre-surgical trials
  • Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer

For information on continuing medical education credits available through SITC's Primer on Tumor Immunology and Cancer Immunotherapy™, please visit our Continuing Education Credit webpage.

Americans with Disabilities Act

handicap.pngEvent staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact SITC prior to the live event at +1 414-271-2456.



Program Organizers

  • Nina Bhardwaj, MD, PhDThe Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai
  • Timothy NJ Bullock, PhDUniversity of Virginia
The SITC Primer on Tumor Immunology and Cancer ImmunotherapyTM is supported in part by grants from Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Merck & Co. Inc., and Pfizer, Inc.